News and Announcements
Blue-Chip Investment | Target Average Distributions of 7.55% p.a
- Published October 19, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
About EG Private Wealth
EG grows the wealth of our private investors through commercial property syndication opportunities. Achieving consistent, above-average returns and capital security, EG takes a personalised and aligned approach to every opportunity.
As a team, we have invested over $250 million of private wealth in the property sector, achieving an average 27.8% IRR. The team you meet at the outset is the team who you will work with throughout the lifecycle of your investment, providing you with hands on, personalised service at every stage.
EG is committed to utilizing property technology to uncover new opportunities and to enhance returns for investors. Our proprietary risk assessment model clearly measures and prices real estate risks, providing a disciplined, data-led approach to decision making.
Our investors include sophisticated wholesale investors, trusts, SMSFs and companies who want investments that deliver strong yields and potential for capital growth in the medium to long term.
Investment Opportunity
EG Private Wealth Company current investment opportunity with average cash distributions 7.55% P.A. for 5 years projected equity IRR at 12% P.A. A long term investment for 5 years with tenant profile as AUSTRALIAN VENUE CO. which is 80% owned by the private equity group, KKR.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
